{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:08:52Z","timestamp":1790636932041,"version":"4.1.0"},"reference-count":47,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Scientific and Technological Developing Scheme of Ji Lin Province","award":["20210204199YY"],"award-info":[{"award-number":["20210204199YY"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n               <jats:title>Background<\/jats:title>\n               <jats:p>Factor Xa (FXa) not only plays an active role in the coagulation cascade but also exerts non-hemostatic signaling through the protease-activated receptors (PARs). This study aimed to investigate whether the FXa inhibitor, Rivaroxaban (RIV), attenuates adverse cardiac remodeling in rats with myocardial infarction (MI) and to identify the underlying molecular mechanisms it uses.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Methods<\/jats:title>\n               <jats:p>An MI model was induced in eight-week-old, male Wistar rats, by permanent ligation of the left anterior descending coronary artery. MI rats were randomly assigned to receive RIV or protease-activated receptors 2-antagonist (PAR-2 antagonist, FSLLRY) treatment for four weeks. Histological staining, echocardiography and hemodynamics were used to assess the cardioprotective effects of RIV. Meanwhile, pharmacological approaches of agonist and inhibitor were used to observe the potential pathways in which RIV exerts antifibrotic effects in neonatal rat cardiac fibroblasts (CFs). In addition, real-time PCR and western blot analysis were performed to examine the associated signaling pathways.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Results<\/jats:title>\n               <jats:p>RIV presented favorable protection of left ventricular (LV) cardiac function in MI rats by significantly reducing myocardial infarct size, ameliorating myocardial pathological damage and improving left ventricular (LV) remodeling. Similar improvements in the PAR-2 antagonist FSLLRY and RIV groups suggested that RIV protects against cardiac dysfunction in MI rats by ameliorating PAR-2 activation. Furthermore, an <jats:italic>in vitro<\/jats:italic> model of fibrosis was then generated by applying angiotensin II (Ang II) to neonatal rat cardiac fibroblasts (CFs). Consistent with the findings of the animal experiments, RIV and FSLLRY inhibited the expression of fibrosis markers and suppressed the intracellular upregulation of transforming growth factor \u03b21 (TGF\u03b21), as well as its downstream Smad2\/3 phosphorylation effectors in Ang II-induced fibrosis, and PAR-2 agonist peptide (PAR-2 AP) reversed the inhibition effect of RIV.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Conclusions<\/jats:title>\n               <jats:p>Our findings demonstrate that RIV attenuates MI-induced cardiac remodeling and improves heart function, partly by inhibiting the activation of the PAR-2 and TGF-\u03b21 signaling pathways.<\/jats:p>\n            <\/jats:sec>","DOI":"10.7717\/peerj.16097","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:58:17Z","timestamp":1695801497000},"page":"e16097","source":"Crossref","is-referenced-by-count":10,"title":["Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-\u03b21 signaling pathways"],"prefix":"10.7717","volume":"11","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikuo","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyuan","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"10.7717\/peerj.16097\/ref-1","doi-asserted-by":"publisher","first-page":"23038","DOI":"10.1074\/jbc.M401376200","article-title":"Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain","volume":"279","author":"Ahamed","year":"2004","journal-title":"Journal of Biological Chemistry"},{"key":"10.7717\/peerj.16097\/ref-2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1160\/TH14-03-0243","article-title":"Tissue factor, protease activated receptors and pathologic heart remodelling","volume":"112","author":"Antoniak","year":"2014","journal-title":"Thrombosis and Haemostasis"},{"key":"10.7717\/peerj.16097\/ref-3","doi-asserted-by":"publisher","first-page":"e81733","DOI":"10.1371\/journal.pone.0081733","article-title":"Protease activated receptor-2 contributes to heart failure","volume":"8","author":"Antoniak","year":"2013","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.16097\/ref-4","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1161\/ATVBAHA","article-title":"Protease-activated receptor 2 deficiency reduces cardiac ischemia\/reperfusion injury","volume":"30","author":"Antoniak","year":"2010","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.7717\/peerj.16097\/ref-5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.thromres.2018.05.015","article-title":"The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction","volume":"167","author":"Bode","year":"2018","journal-title":"Thrombosis Research"},{"key":"10.7717\/peerj.16097\/ref-6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.119.039609","article-title":"RIV with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease","volume":"140","author":"Branch","year":"2019","journal-title":"Circulation"},{"key":"10.7717\/peerj.16097\/ref-7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.pharmtox.45.120403.095802","article-title":"The cardiac fibroblast: therapeutic target in myocardial remodeling and failure","volume":"45","author":"Brown","year":"2005","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.7717\/peerj.16097\/ref-8","doi-asserted-by":"publisher","first-page":"37319","DOI":"10.1074\/jbc.M113.492793","article-title":"Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-beta receptor signaling pathways contributes to renal fibrosis","volume":"288","author":"Chung","year":"2013","journal-title":"Journal of Biological Chemistry"},{"key":"10.7717\/peerj.16097\/ref-9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"RIV with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"10.7717\/peerj.16097\/ref-10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.phrs.2015.07.001","article-title":"Cardiac fibroblasts as sentinel cells in cardiac tissue: receptors, signaling pathways and cellular functions","volume":"101","author":"Diaz-Araya","year":"2015","journal-title":"Pharmacological Research"},{"key":"10.7717\/peerj.16097\/ref-11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"RIV with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.16097\/ref-12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/TH13-09-0730","article-title":"Targeting factor Xa and thrombin: impact on coagulation and beyond","volume":"111","author":"Esmon","year":"2014","journal-title":"Thrombosis and Haemostasis"},{"key":"10.7717\/peerj.16097\/ref-13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-61779-523-7_20","article-title":"Isolation of cardiac myocytes and fibroblasts from neonatal rat pups","volume":"843","author":"Golden","year":"2012","journal-title":"Methods in Molecular Biology"},{"key":"10.7717\/peerj.16097\/ref-14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/SHK.0000000000001412","article-title":"Direct RIV-induced factor XA inhibition proves to be cardioprotective in rats","volume":"53","author":"Guillou","year":"2020","journal-title":"Shock"},{"issue":"13","key":"10.7717\/peerj.16097\/ref-15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJMra072139","article-title":"Cardiac plasticity","volume":"358","author":"Hill","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.7717\/peerj.16097\/ref-16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jbiomech.2009.09.020","article-title":"The myofibroblast: paradigm for a mechanically active cell","volume":"43","author":"Hinz","year":"2010","journal-title":"Journal of Biomechanics"},{"key":"10.7717\/peerj.16097\/ref-17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/01.ATV.0000251995.73307.2d","article-title":"The roles of proteinase-activated receptors in the vascular physiology and pathophysiology","volume":"27","author":"Hirano","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.7717\/peerj.16097\/ref-18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1248\/bpb.b20-01011","article-title":"RIV attenuates right ventricular remodeling in rats with pulmonary arterial hypertension","volume":"44","author":"Imano","year":"2021","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.7717\/peerj.16097\/ref-19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jphs.2018.07.002","article-title":"Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia","volume":"137","author":"Imano","year":"2018","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.7717\/peerj.16097\/ref-20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jacbts.2021.09.010","article-title":"RIV, a direct oral factor Xa inhibitor, attenuates atherosclerosis by alleviating factor Xa-PAR-2-mediated autophagy suppression","volume":"6","author":"Ito","year":"2021","journal-title":"JACC: Basic to Translational Science"},{"issue":"1","key":"10.7717\/peerj.16097\/ref-21","first-page":"11","article-title":"Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases","volume":"52","author":"Kim","year":"2000","journal-title":"Pharmacological Reviews"},{"issue":"4","key":"10.7717\/peerj.16097\/ref-22","doi-asserted-by":"publisher","first-page":"a022293","DOI":"10.1101\/cshperspect.a022293","article-title":"TGF-beta1 signaling and tissue fibrosis","volume":"10","author":"Kim","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.7717\/peerj.16097\/ref-23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/hep.24784","article-title":"Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells","volume":"55","author":"Knight","year":"2012","journal-title":"Hepatology"},{"key":"10.7717\/peerj.16097\/ref-24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jjcc.2017.08.007","article-title":"Possible role of RIV in attenuating pressure-overload-induced atrial fibrosis and fibrillation","volume":"71","author":"Kondo","year":"2018","journal-title":"Journal of Cardiology"},{"issue":"11","key":"10.7717\/peerj.16097\/ref-25","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.110.217737","article-title":"Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation","volume":"106","author":"Leask","year":"2010","journal-title":"Circulation Research"},{"key":"10.7717\/peerj.16097\/ref-26","doi-asserted-by":"publisher","first-page":"739212","DOI":"10.3389\/fcvm.2021.739212","article-title":"RIV suppresses atherosclerosis by inhibiting FXa-induced macrophage M1 polarization-mediated phenotypic conversion of vascular smooth muscle cells","volume":"8","author":"Ma","year":"2021","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10.7717\/peerj.16097\/ref-27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","article-title":"TGFbeta signalling in context","volume":"13","author":"Massague","year":"2012","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.7717\/peerj.16097\/ref-28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1161\/HYPERTENSIONAHA.111.169417","article-title":"Tryptase\/Protease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts","volume":"58","author":"McLarty","year":"2011","journal-title":"Hypertension"},{"issue":"1","key":"10.7717\/peerj.16097\/ref-29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"RIV in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.16097\/ref-30","doi-asserted-by":"publisher","first-page":"52206","DOI":"10.3791\/52206","article-title":"Permanent ligation of the left anterior descending coronary artery in mice: a model of post-myocardial infarction remodelling and heart failure","volume":"(94)","author":"Muthuramu","year":"2014","journal-title":"Journal of Visualized Experiments"},{"key":"10.7717\/peerj.16097\/ref-31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1253\/circrep.CR-19-0117","article-title":"Cardioprotective effects of rivaroxaban on cardiac remodeling after experimental myocardial infarction in mice","volume":"2","author":"Nakanishi","year":"2020","journal-title":"Circulation Reports"},{"key":"10.7717\/peerj.16097\/ref-32","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41440-021-00700-7","article-title":"RIV attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice","volume":"44","author":"Narita","year":"2021","journal-title":"Hypertension Research"},{"key":"10.7717\/peerj.16097\/ref-33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1177\/0003319719840861","article-title":"Nonhemostatic activities of factor Xa: are there pleiotropic effects of anti-FXa direct oral anticoagulants?","volume":"70","author":"Papadaki","year":"2019","journal-title":"Angiology"},{"key":"10.7717\/peerj.16097\/ref-34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pharmthera.2009.05.002","article-title":"Cardiac fibroblasts: at the heart of myocardial remodeling","volume":"123","author":"Porter","year":"2009","journal-title":"Pharmacology and Therapeutics"},{"key":"10.7717\/peerj.16097\/ref-35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","article-title":"The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis","volume":"119","author":"Prabhu","year":"2016","journal-title":"Circulation Research"},{"key":"10.7717\/peerj.16097\/ref-36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardiores.2004.04.030","article-title":"TGF-beta1 and angiotensin networking in cardiac remodeling","volume":"63","author":"Rosenkranz","year":"2004","journal-title":"Cardiovascular Research"},{"issue":"6","key":"10.7717\/peerj.16097\/ref-37","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/01.HYP.36.6.978","article-title":"Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension","volume":"36","author":"Sechi","year":"2000","journal-title":"Hypertension"},{"key":"10.7717\/peerj.16097\/ref-38","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/resp.13415","article-title":"TGF-beta: master regulator of inflammation and fibrosis","volume":"23","author":"Stewart","year":"2018","journal-title":"Respirology"},{"key":"10.7717\/peerj.16097\/ref-39","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1038\/s41598-017-05190-7","article-title":"ENMD-1068 inhibits liver fibrosis through attenuation of TGF-beta1\/Smad2\/3 signaling in mice","volume":"7","author":"Sun","year":"2017","journal-title":"Scientific Reports"},{"issue":"125","key":"10.7717\/peerj.16097\/ref-40","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.101.25.2981","article-title":"Left ventricular remodeling after myocardial infarction: pathophysiology and therapy","volume":"101","author":"Sutton","year":"2000","journal-title":"Circulation"},{"key":"10.7717\/peerj.16097\/ref-41","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1093\/cvr\/cvaa263","article-title":"Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment","volume":"117","author":"Ten Cate","year":"2021","journal-title":"Cardiovascular Research"},{"issue":"3","key":"10.7717\/peerj.16097\/ref-42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/biom10030487","article-title":"TGF-beta Signaling","volume":"10","author":"Tzavlaki","year":"2020","journal-title":"Biomolecules"},{"issue":"8","key":"10.7717\/peerj.16097\/ref-43","doi-asserted-by":"publisher","first-page":"e003315","DOI":"10.1161\/CIRCHEARTFAILURE.116.003315","article-title":"Targeting the cardiac myofibroblast secretome to treat myocardial fibrosis in heart failure","volume":"9","author":"Weber","year":"2016","journal-title":"Circulation: Heart Failure"},{"issue":"1","key":"10.7717\/peerj.16097\/ref-44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrcardio.2012.158","article-title":"Myofibroblast-mediated mechanisms of pathological remodelling of the heart","volume":"10","author":"Weber","year":"2013","journal-title":"Nature Reviews Cardiology"},{"issue":"12","key":"10.7717\/peerj.16097\/ref-45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/jcm5120111","article-title":"Proteinase-activated receptor 2 is a novel regulator of TGF-beta signaling in pancreatic cancer","volume":"5","author":"Witte","year":"2016","journal-title":"Journal of Clinical Medicine"},{"key":"10.7717\/peerj.16097\/ref-46","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jcin.2022.01.285","article-title":"Prophylactic RIV therapy for left ventricular thrombus after anterior ST-segment elevation myocardial infarction","volume":"15","author":"Zhang","year":"2022","journal-title":"JACC: Cardiovascular Interventions"},{"key":"10.7717\/peerj.16097\/ref-47","doi-asserted-by":"publisher","first-page":"e001956","DOI":"10.1161\/CIRCGEN.117.001956","article-title":"Coagulation factors and the risk of ischemic heart disease: a mendelian randomization study","volume":"11","author":"Zhao","year":"2018","journal-title":"Circulation: Genomic and Precision Medicine"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/16097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/16097.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/16097.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/16097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:58:33Z","timestamp":1695801513000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/16097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":47,"alternative-id":["10.7717\/peerj.16097"],"URL":"https:\/\/doi.org\/10.7717\/peerj.16097","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"article-number":"e16097"}}